Physician profile
William Ross Stone
NPI 1346530599
$1,940.31
in general payments reported to CMS, 2019-2025
21 companies · $187 in 2025
The $187 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $140 · 2021: $334 · 2022: $354 · 2023: $483 · 2024: $202 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $871.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $674.77 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Intra-Sana Laboratories | $150.00 | 2022-2023 | Reltone 200 Mg, Reltone 400 Mg |
| Boston Scientific Corporation | $133.23 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.43 | 2019-2024 | Trulance |
| Gilead Sciences, INC. | $125.00 | 2023 | Epclusa |
| Lilly USA, LLC | $85.23 | 2025 | Omvoh |
| Genzyme Corporation | $84.77 | 2024-2025 | |
| Celgene Corporation | $74.78 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $73.17 | 2019-2023 | Entyvio |
| Janssen Biotech, INC. | $61.71 | 2021 | |
| Dova Pharmaceuticals | $59.51 | 2019 | |
| Pfizer INC. | $59.02 | 2019-2024 | |
| Medtronic, INC. | $51.64 | 2022-2025 | Kyphon Express II Kyphopak Tray |
| Braintree Laboratories, INC. | $36.21 | 2022-2023 | Sutab |
| Intercept Pharmaceuticals, INC. | $32.34 | 2019-2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $26.99 | 2021-2022 | |
| Daiichi Sankyo INC. | $23.81 | 2020 | |
| Qol Medical, LLC | $16.95 | 2022 | |
| Madrigal Pharmaceuticals | $16.05 | 2024 | Resmetirom |
| Enterra Medical, INC. | $13.27 | 2022 | |
| Evoke Pharma, INC. | $12.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.